{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:52:21Z","timestamp":1759539141983,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.arbres.2021.05.021","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T17:29:10Z","timestamp":1622827750000},"page":"194-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pleural Effusion Occurring During Lung Cancer Immunotherapy: A Challenge for the Clinician"],"prefix":"10.1016","volume":"58","author":[{"given":"Lucile","family":"Roussel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Brindel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celsio","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gauthier","family":"Treffel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Billon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Tiotiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2021.05.021_bib0105","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jtho.2016.10.008","article-title":"Anti-PD-1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Reungwetwattana","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.arbres.2021.05.021_bib0110","doi-asserted-by":"crossref","first-page":"eaat2702","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.arbres.2021.05.021_bib0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.arbres.2021.05.021_bib0120","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00262-020-02726-1","article-title":"Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review","volume":"70","author":"Suliman","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.arbres.2021.05.021_bib0125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/0284186X.2015.1125017","article-title":"Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma","volume":"55","author":"Lee","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.arbres.2021.05.021_bib0130","unstructured":"8th edition of the TNM classification system slides. IASLC. https:\/\/www.iaslc.org\/research-education\/publications-resources-guidelines\/8th-edition-tnm-classification-system-slides [cited 16.04.21]"},{"key":"10.1016\/j.arbres.2021.05.021_bib0135","unstructured":"Modified Medical Research Council Dyspnea Scale. https:\/\/www.mdcalc.com\/mmrc-modified-medical-research-council-dyspnea-scale\/ [cited 16.04.21]"},{"key":"10.1016\/j.arbres.2021.05.021_bib0140","article-title":"Findings on chest ct performed in the emergency department in patients on immune checkpoint inhibitor therapy: single-institution 8-year experience in 136 patients","author":"Smith","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.arbres.2021.05.021_bib0145","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2021.05.021_bib0150","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/annonc\/mdx214","article-title":"Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment","volume":"28","author":"Yanagihara","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arbres.2021.05.021_bib0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.trecan.2020.01.005","article-title":"Hyperprogression and immunotherapy: fact fiction, or alternative fact?","volume":"6","author":"Adashek","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.arbres.2021.05.021_bib0160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arbres.2021.05.021_bib0165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arbres.2021.05.021_bib0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2021.02.005","article-title":"Post-progression outcomes of NSCLC patients with PD-L1 expression \u226550% receiving first-line single-agent pembrolizumab in a large multicentre real-world study","volume":"148","author":"Cortellini","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.arbres.2021.05.021_bib0175","doi-asserted-by":"crossref","first-page":"190058","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2021.05.021_bib0180","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arbres.2021.05.021_bib0185","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2020.03.015","article-title":"Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature","volume":"132","author":"Zaemes","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.arbres.2021.05.021_bib0190","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.3389\/fimmu.2020.02006","article-title":"Diagnosis for latent tuberculosis infection: new alternatives","volume":"11","author":"Carranza","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2021.05.021_bib0195","doi-asserted-by":"crossref","first-page":"00258","DOI":"10.1183\/23120541.00258-2018","article-title":"Comparison of the QuantiFERON-TB and tuberculin skin test for detection of latent tuberculosis infection in cancer patients in a developing country","volume":"5","author":"Galindo","year":"2019","journal-title":"ERJ Open Res"},{"year":"2018","series-title":"Review of reviews and guidelines on target groups, diagnosis, treatment and programmatic issues for implementation of latent tuberculosis management","key":"10.1016\/j.arbres.2021.05.021_bib0200"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289621001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289621001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:41:13Z","timestamp":1759531273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289621001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0300289621001770"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2021.05.021","relation":{},"ISSN":["0300-2896"],"issn-type":[{"type":"print","value":"0300-2896"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleural Effusion Occurring During Lung Cancer Immunotherapy: A Challenge for the Clinician","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2021.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}